Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride

@article{Rabiner2002EvaluationOE,
  title={Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride},
  author={Eugenii A. Rabiner and Roger N. Gunn and Martin R. Wilkins and Ewen Sedman and Paul M. Grasby},
  journal={Journal of Psychopharmacology},
  year={2002},
  volume={16},
  pages={195 - 199}
}
The use of so-called, atypical antipsychotic medication is becoming more widespread in the treatment of psychotic disorders. EMD 128 130 is a novel compound acting as an agonist at the 5-HT1A receptor, and as an antagonist at the dopamine-2 (D2) receptor. This dual action may confer additional benefits over selective D2 antagonists in the treatment of psychotic disorders. In this study, we investigated the occupancy of EMD 128 130 in vivo at the human D2 and 5-HT1A receptors with positron… Expand
Occupancy of Agonist Drugs at the 5-HT1A Receptor
TLDR
It is concluded that 5-HT1A receptor agonists produce detectable occupancy only at higher doses that would produce unacceptable levels of side effects in man, although lower doses are sufficient to produce pharmacological effects. Expand
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
TLDR
Aripiprazole exhibits a unique occupancy profile as compared with other conventional and atypical antipsychotics, and the threshold for response appears to be higher than 60%, extrapyramidal side effects appear to be uncommon even at occupancies that exceed the conventional extrapYramidal Side effects threshold of 80%, and 5-HT(2) occupancy is lower than D( 2) occupancy. Expand
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets
TLDR
It is shown that NLX-112 has anti-LID activity at the doses tested as well as reducing motor disability, suggesting that it may have motor facilitation effects of its own. Expand
Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson's Disease and Levodopa-Induced Dyskinesia: A microPET Study.
TLDR
The data suggest that agonist and antagonist 5-HT1A receptor-binding sites are differently modified in Parkinson's disease and levodopa-induced dyskinesia and emphasize the need to characterize this state using agonist radiotracers in physiological and pathological conditions. Expand
A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment
TLDR
The results obtained in vivo bring into question the importance of the receptor in thepathophysiology of the illness and suggest that 5-HT1A agonists do not appear to measurably block the binding of antagonist radiotracers in man at doses that are pharmacologically active but which are limited by tolerability. Expand
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
TLDR
It is demonstrated that some putative antipsychotics with pronounced 5-HT1A agonists activity, coupled with partial agonist activity at DA D2 receptors, markedly diminish PPI of the startle reflex in rats, raising the issue of the influence of such compounds on sensorimotor gating in humans. Expand
SEP-225289 Serotonin and Dopamine Transporter Occupancy: A PET Study
SEP-225289 is a novel compound that, based on in vitro potencies for transporter function, potentially inhibits reuptake at dopamine, norepinephrine, and serotonin transporters. An open-label PETExpand
Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone
TLDR
The finding of a relationship between 5-HT1A binding and the degree of improvement in negative symptoms provides further support for the role of the 5- HT1A receptor in the pathophysiology and treatment of this symptom domain. Expand
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676
TLDR
The properties of AZD3676 showed preclinical properties consistent with CNS drug potential, including nanomolar receptor affinity and efficacy in rodent models of learning and memory, and these findings support the further integrated use of PET for confirmation of multitarget occupancy of CNS drugs. Expand
The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors
TLDR
The functional effects of sarizotan on human D2-like dopamine receptors (D2S, D2L, D3, D4.4) individually expressed in the AtT-20 neuroendocrine cell line are reported. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635.
TLDR
The utility of PET in aiding novel drug development is demonstrated as it demonstrated a preferential occupancy at the autoreceptor compared to the postsynaptic receptor over a plasma range of about 10-20 ng/mL. Expand
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
TLDR
Clozapine, at doses known to be effective in routine clinical settings, showed a D 2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antippsychotics. Expand
Quantifying drug-related 5-HT1A receptor occupancy with [18F]MPPF
TLDR
It is established that the binding potential (BP=Bmax/KD) of [18F]MPPF for cerebral 5-HT1A receptors can be assessed in human brain without arterial sampling and can be of particular interest in determining the 5- HT1A receptor interaction of new or established drugs in phase 1 and early phase 2 drug trials. Expand
Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development.
TLDR
Three studies are reviewed to demonstrate the suitability of WAY as radioligand for quantification of central 5-HT(1A) receptors in brain and as an applicable tool for drug development and corroborate that quantitative neuroimaging of receptor binding has potential for the evaluation and dose finding of new central nervous system drugs. Expand
β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro: Implications for Antidepressant Therapy
TLDR
The data reveal that pindolol doses used in antidepressant trials so far are suboptimal for significant occupancy at the 5-HT1A autoreceptor. Expand
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
TLDR
This finding indicates that neuroleptic-induced extrapyramidal syndromes are related to the degree of central D2 occupancy induced in the basal ganglia of drug-treated schizophrenic patients and demonstrates that clozapine is also "atypical" with respect to the central D1 occupancy in patients. Expand
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
TLDR
Clinical doses of all the currently used classes of antipsychotic drugs cause a substantial blockade of central D2-dopamine receptors in humans, and this effect appears to be selective for the antipsychotics. Expand
A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables
TLDR
The binding of [(11)C]WAY-100635 was insensitive to changes in brain 5-HT induced by tryptophan infusion and depletion and there were no significant correlations of regional and global BP with common radiochemical, demographic, physiological, and personality variables. Expand
Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia.
TLDR
It is suggested that there are GTP-sensitive 5-HT1A sites in the human brain and that selective increases in G TP-sensitive 4-HT2 and 3-HT3 related compounds in the prefrontal and temporal cortices of schizophrenics relate to the pathophysiology of schizophrenia. Expand
Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET
TLDR
It is concluded that a simplified reference tissue approach may be used to quantify 5-HT1A binding either in terms of ROI data or as parametric images. Expand
...
1
2
3
4
...